Online inquiry

IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10945MR)

This product GTTS-WQ10945MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets HAVCR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_032782.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84868
UniProt ID Q8TDQ0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10945MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14220MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ12841MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ15703MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ5774MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ10943MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ9230MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ14450MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ5688MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW